LeMaitre Vascular Inc - Asset Resilience Ratio
LeMaitre Vascular Inc (LMAT) has an Asset Resilience Ratio of 53.10% as of September 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Read LMAT liabilities breakdown for a breakdown of total debt and financial obligations.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2004–2024)
This chart shows how LeMaitre Vascular Inc's Asset Resilience Ratio has changed over time. See LeMaitre Vascular Inc net assets for net asset value and shareholders' equity analysis.
Liquid Assets Composition Over Time
This chart breaks down LeMaitre Vascular Inc's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see LMAT market cap.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $317.56 Million | 53.1% |
| Total Liquid Assets | $317.56 Million | 53.10% |
Asset Resilience Insights
- Very High Liquidity: LeMaitre Vascular Inc maintains exceptional liquid asset reserves at 53.10% of total assets.
- This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
- The company has significant short-term investments, indicating active treasury management.
LeMaitre Vascular Inc Industry Peers by Asset Resilience Ratio
Compare LeMaitre Vascular Inc's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Gan & Lee Pharmaceuticals Co Ltd
SHG:603087 |
Medical Instruments & Supplies | 9.08% |
|
Vizionfocus Inc.
TW:4771 |
Medical Instruments & Supplies | 5.07% |
|
Ansell Ltd
AU:ANN |
Medical Instruments & Supplies | 4.42% |
|
Nanosonics Ltd
AU:NAN |
Medical Instruments & Supplies | 51.82% |
|
SDI Ltd
AU:SDI |
Medical Instruments & Supplies | 6.36% |
|
Austco Healthcare Ltd
AU:AHC |
Medical Instruments & Supplies | 15.90% |
|
Trajan Group Holdings Ltd
AU:TRJ |
Medical Instruments & Supplies | 0.23% |
|
Osteopore Ltd
AU:OSX |
Medical Instruments & Supplies | 43.09% |
Annual Asset Resilience Ratio for LeMaitre Vascular Inc (2004–2024)
The table below shows the annual Asset Resilience Ratio data for LeMaitre Vascular Inc.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2024-12-31 | 49.67% | $274.11 Million | $551.82 Million | +26.37pp |
| 2023-12-31 | 23.30% | $80.81 Million | $346.78 Million | +2.83pp |
| 2022-12-31 | 20.47% | $63.56 Million | $310.48 Million | +1.31pp |
| 2021-12-31 | 19.16% | $56.10 Million | $292.80 Million | +19.08pp |
| 2020-12-31 | 0.08% | $214.00K | $252.81 Million | -11.01pp |
| 2019-12-31 | 11.09% | $20.89 Million | $188.34 Million | -3.06pp |
| 2018-12-31 | 14.15% | $21.67 Million | $153.09 Million | -3.71pp |
| 2017-12-31 | 17.86% | $22.56 Million | $126.32 Million | -- |
| 2016-12-31 | 0.00% | $0.00 | $101.92 Million | -- |
| 2015-12-31 | 0.00% | $0.00 | $90.70 Million | -- |
| 2014-12-31 | 0.00% | $0.00 | $81.49 Million | -- |
| 2013-12-31 | 0.00% | $0.00 | $70.49 Million | -- |
| 2012-12-31 | 0.00% | $0.00 | $63.06 Million | -- |
| 2011-12-31 | 0.00% | $0.00 | $59.69 Million | -- |
| 2009-12-31 | 1.42% | $808.00K | $56.91 Million | -8.43pp |
| 2008-12-31 | 9.85% | $5.36 Million | $54.40 Million | -16.64pp |
| 2007-12-31 | 26.49% | $16.20 Million | $61.15 Million | -0.58pp |
| 2006-12-31 | 27.06% | $15.42 Million | $56.96 Million | +25.60pp |
| 2004-12-31 | 1.46% | $300.00K | $20.50 Million | -- |
About LeMaitre Vascular Inc
LeMaitre Vascular, Inc. develops, manufactures, and markets medical devices and implants used in the field of vascular surgery in the Americas, Europe, the Middle Esat, Africa, and the Asia Pacific. The company offers allografts, which are cryopreserved human tissue grafts used in vascular reconstruction, and cardiac repair and reconstruction; embolectomy catheters to remove blood clots from arte… Read more